• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MARPAI REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

    5/9/24 4:01:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email

    Reduces Operating Expense by over $5 million and Net Loss by over 50% compared to 2023

    TAMPA, Fla., May 9, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (NASDAQ:MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced financial results for the first quarter of 2024. The Company expects to hold a webcast to discuss the results on May 10, 2024.

    Q1 2024 Financial Highlights:

    • Net revenues were approximately $7.4 million for the three months ended March 31, 2024, down $2.3 million, or 24% lower year over year, compared to the three months ended March 31, 2023.
    • Gross profit was $2.5 million for the three months ended March 31, 2024, down $0.7 million, or 23% lower year over year compared to the three months ended March 31, 2023.
    • Operating expenses were $6.6 million for the three months ended March 31, 2024, an improvement of $5.2 million, or 44% lower year over year compared to the three months ended March 31, 2023.
    • Operating loss was $4.1 million for the three months ended March 31, 2024, an improvement of $4.5 million, or 52% lower year over year compared to the three months ended March 31, 2023.
    • Net loss was $4.3 million for the three months ended March 31, 2024, an improvement of $4.5 million, or 51% lower year over year compared to the three months ended March 31, 2023.
    • Basic and diluted earnings per share were ($0.46) for the three months ended March 31, 2024, an improvement of $1.22 per share year over year compared to the three months ended March 31, 2023.

    "The market is evolving, and we're adapting our approach to better serve our clients' needs. While we saw some client turnover in the first quarter, we are confident that our new initiatives will lead to long-term revenue growth and profitability," said Damien Lamendola, Chief Executive Officer of Marpai. "We are very pleased to have added a new "off cycle" client in Q1 and the expansion of our sales team with two highly successful industry executives."

    John Powers, Marpai President commented, "Marpai is delivering on its promise to save! Our focus on operational efficiency has significantly reduced operating expenses. Building on this success, as previously announced, we implemented an additional cost-reduction program expected to generate $3 million in annual savings. Marpai remains dedicated to its core mission: reducing client costs and improving member care through continuous operational and financial improvements."

    Webcast and Conference Call Information

    Marpai expects to host a conference call and webcast on Friday, May 10, 2024, at 8:30 a.m. ET to answer questions about the Company's operational and financial highlights for its first quarter ended March 31, 2024.

    Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/MVqDW74kNpl

    About Marpai, Inc.

    Marpai, Inc. (NASDAQ:MRAI) is a leading, national TPA company bringing value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com.

    Forward-Looking Statement Disclaimer

    This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses that it is confident that its new initiatives will lead to long-term revenue growth and profitability and that its additional cost-reduction program is expected to generate $3 million in annual savings. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

    More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEET

    (in thousands, except share and per share data)

    (Unaudited)







    March 31, 2024



    December 31, 2023











    ASSETS:









    Current assets:









    Cash and cash equivalents



    $                851



    $                    1,147

    Restricted cash



    12,761



    12,345

    Accounts receivable, net of allowance for credit losses of $25 and $25



    366



    1,124

    Unbilled receivable



    727



    768

    Due from buyer for sale of business unit



    800



    800

    Prepaid expenses and other current assets



    1,000



    901

    Total current assets



    16,505



    17,085











    Property and equipment, net



    579



    611

    Capitalized software, net



    1,512



    2,127

    Operating lease right-of-use assets



    2,311



    2,373

    Goodwill



    3,018



    3,018

    Intangible assets, net



    4,874



    5,177

    Security deposits 



    1,267



    1,267

    Other long-term asset



    22



    22

    Total assets



    $           30,088



    $                  31,680

    LIABILITIES AND STOCKHOLDERS'  (DEFICIT) EQUITY









    Current liabilities:









    Accounts payable



    $             3,824



    $                    4,649

    Accrued expenses



    3,076



    2,816

    Accrued fiduciary obligations



    9,510



    11,573

    Deferred revenue



    1,481



    661

    Current portion of operating lease liabilities



    523



    512

    Other short-term liabilities



    1,709



    632

    Total current liabilities



    20,123



    20,843











    Other long-term liabilities



    19,724



    19,401

    Operating lease liabilities, net of current portion



    3,547



    3,684

    Deferred tax liabilities



    1,190



    1,190

    Total liabilities



    44,584



    45,118

    COMMITMENTS AND CONTINGENCIES









    STOCKHOLDERS' (DEFICIT) EQUITY









    Common stock, $0.0001 par value, 227,791,050 shares authorized; 10,308,038 shares

       and 7,960,938 shares issued and outstanding at March 31, 2024 and

       December 31, 2023, respectively (1)



    1



    1

    Additional paid-in capital



    66,595



    63,307

    Accumulated deficit



    (81,092)



    (76,746)

    Total stockholders' (deficit) equity



    (14,496)



    (13,438)

    Total liabilities and stockholders' (deficit) equity



    $           30,088



    $                  31,680



    (1) Reflects 1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

    (in thousands, except share and per share data)

    (Unaudited)







    Three Months Ended 





    March 31, 2024



    March 31, 2023

    Revenue



    $             7,385



    $                    9,672

    Costs and expenses









    Cost of revenue (exclusive of depreciation and amortization

       shown separately below)



    4,871



    6,409

    General and administrative



    3,421



    5,226

    Sales and marketing



    602



    2,179

    Information technology



    1,124



    2,187

    Research and development



    7



    500

    Depreciation and amortization



    951



    1,044

    Facilities



    474



    650

    Total costs and expenses



    11,450



    18,195

    Operating loss



    (4,065)



    (8,523)

    Other income (expenses)









    Other income



    120



    50

    Interest expense, net



    (398)



    (385)

    Foreign exchange (loss) gain



    (3)



    (15)

    Loss before provision for income taxes



    (4,346)



    (8,873)

    Income tax expense



    —



    —

    Net loss



    $            (4,346)



    $                  (8,873)

    Net loss per share, basic & fully diluted (1)



    $              (0.46)



    $                    (1.68)

    Weighted average common shares outstanding, basic and

       diluted (1)



    9,405,775



    5,290,661



    (1) Reflects 1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands, except share and per share data)

    (Unaudited)







    Three Months Ended





    March 31, 2024



    March 31, 2023

    Cash flows from operating activities:









    Net loss



    $            (4,346)



    $                  (8,873)

    Adjustments to reconcile net loss to net cash used in operating activities:









    Depreciation and amortization



    951



    1,044

    Share-based compensation



    561



    623

    Common stock issued to vendors in exchange for services



    —



    79

    Amortization of right-of-use asset



    62



    252

    Non-cash interest



    423



    388

    Changes in operating assets and liabilities:









    Accounts receivable and unbilled receivable



    800



    (239)

    Prepaid expense and other assets



    (99)



    162

    Accounts payable



    (825)



    653

    Accrued expenses



    215



    (1,416)

    Accrued fiduciary obligations



    (2,063)



    —

    Operating lease liabilities



    (126)



    (363)

    Other liabilities



    862



    1,149

    Net cash used in operating activities



    (3,585)



    (6,541)

    Cash flows from investing activities:









    Disposal of property and equipment



    —



    3

    Net cash provided by investing activities



    —



    3

    Cash flows from financing activities:









    Proceeds from sale of future cash receipts on accounts receivable



    1,509



    —

    Payments to buyer of receivables



    (57)



    —

    Payments to seller for acquisition



    (474)



    —

    Proceeds from issuance of common stock in a public offering, net



    2,727



    —

    Net cash provided by financing activities



    3,705



    —











    Net increase (decrease) in cash, cash equivalents and restricted cash



    120



    (6,538)











    Cash, cash equivalents and restricted cash at beginning of period



    13,492



    23,117

    Cash, cash equivalents and restricted cash at end of period



    $           13,612



    $                  16,579











    Reconciliation of cash, cash equivalents, and restricted cash reported in

       the condensed consolidated balance sheet









    Cash and cash equivalents



    $                851



    $                    6,174

    Restricted cash



    12,761



    10,405

    Total cash, cash equivalents and restricted cash shown in the condensed

       consolidated statement of cash flows



    $           13,612



    $                  16,579

    Supplemental disclosure of non-cash activity









    Measurement period adjustment to Goodwill



    $                  —



    $                         36

     

    (PRNewsfoto/Marpai)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-reports-first-quarter-2024-financial-results-302141613.html

    SOURCE Marpai

    Get the next $MRAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer Scrip Dallas was granted 100,000 shares (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:48:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Pons Robert M bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 16% to 359,200 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:47:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    SEC Filings

    View All

    Marpai Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement

    8-K - Marpai, Inc. (0001844392) (Filer)

    1/23/26 4:02:33 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marpai Inc.

    SCHEDULE 13G/A - Marpai, Inc. (0001844392) (Subject)

    1/9/26 2:43:57 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    12/22/25 7:14:49 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI ANNOUNCES 2026 MOMENTUM AND KEY PARTNERSHIP EXPANSION

    Renews Aetna Signature Administrator Network Agreement and Enhances Cost Containment with Faircost Optimizer TAMPA, Fla., Dec. 1, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced significant positive momentum heading into the new year, highlighted by a better-than-expected sales cycle for 2026 and the renewal of its critical network access agreement with Aetna. The Company reports a robust sales cycle, securing a volume of new clients for January 1, 2026, that surpasses internal expectations, reinforcing its path to scalable growt

    12/1/25 4:04:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Financials

    Live finance-specific insights

    View All

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

    TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q3 Financial Results Conference Call Date: November 13, 2025 Time: 8:30 a.m. Eastern Time Call: US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:  https://app.webinar.net/934VMynbB6a Follow us on X.com and LinkedIn You may str

    11/6/25 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut 70% as Turnaround Gains Traction TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substantial quarterly year-over-year improvements across key financial metrics: Operating expenses down 70%, saving $9.9 millionOperating loss reduced by 71% to $3.6 million, an $8.7 million improvementNet loss reduced by 66% to $4.4 million, als

    8/13/25 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

    Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

    5/13/25 9:01:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

    STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

    1/22/25 5:00:00 PM ET
    $HIT
    $MRAI
    Specialty Insurers
    Finance
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care